Oklahoma HB 2107: Controlled dangerous substances; authorizing certain scientific research and clinical trials related to psilocybin and psilocyn; requiring registration; providing certain immunities; effective date.

Status: Second Reading referred to Health and Human Services Committee then to Appropriations Committee (as of 2023-03-29)

State: Oklahoma · Session: 2024 · Bill: HB 2107

Sponsors: Brooks, Pae

View Oklahoma HB 2107 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.